On June 2, Medline Inc declined 5.03% in regular trading, trading at $33.98 per share, with trading volume of approximately $202 million.

On the news front, major shareholder sell-offs and a recent large secondary offering are weighing heavily on the stock. The company disclosed 12 insider transactions on June 1, revealing that shareholders holding over 10% of shares — including BCP 8 Holdings Mozart Manager and affiliated entities — collectively sold approximately 98.5 million shares on May 28 at an average price of $36.54, totaling roughly $35.99 billion in proceeds.

Additionally, just days prior on May 29, certain selling stockholders completed an upsized secondary offering of 72.6 million shares of Class A common stock priced at $37.00 per share, with underwriters granted a 30-day option to purchase up to an additional 10.9 million shares. Medline did not sell any shares in the offering and will not receive any proceeds. The combination of the massive secondary placement and concentrated insider selling has created significant supply-side pressure, driving shares well below both the offering price and the insider transaction price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)